Cargando…

A Randomized Controlled Trial Comparing BioMime Sirolimus-Eluting Stent With Everolimus-Eluting Stent: Two-Year Outcomes of the meriT-V Trial

BACKGROUND: Drug-eluting stents (DESs) based on biodegradable polymers (BPs) have been introduced to reduce the risk for late and very late stent thrombosis (ST), which were frequently observed with earlier generations of DES designs based on durable polymers (DPs); however, randomized controlled tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abizaid, Alexandre, Costa, Ricardo, Kedev, Sasko, Kedhi, Elvin, Talwar, Suneel, Erglis, Andrejs, Hlinomaz, Ota, Masotti, Monica, Fath-Ordoubadi, Farzin, Milewski, Krzysztof, Lemos, Pedro, Botelho, Roberto, Ijsselmuiden, Alexander, Koolen, Jacques, Kala, Petr, Janssens, Luc, Chandra, Udita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409544/ https://www.ncbi.nlm.nih.gov/pubmed/37559713 http://dx.doi.org/10.14740/cr1498

Ejemplares similares

One-year outcomes of a BioMime™ Sirolimus-Eluting Coronary Stent System with a biodegradable polymer in all-comers coronary artery disease patients: The meriT-3 study
por: Jain, Rajendra Kumar, et al.
Publicado: (2016)

Sirolimus-eluting coronary stents: a review
por: Abizaid, Alexandre
Publicado: (2007)

Use of BioMime Morph stent in treating left main triple vessel disease: a case report
por: Sharma, Yash Paul, et al.
Publicado: (2020)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
por: Ouyang, Hang, et al.
Publicado: (2021)

Estrogen-Eluting Stents
por: Ryu, Sung Kee, et al.
Publicado: (2009)

Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent
por: Kim, Ung, et al.
Publicado: (2011)

Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy
por: Hawranek, Michał, et al.
Publicado: (2021)

Long-Term Assessment of Thin-Strut BioMime Coronary Stent System in Real-World Population at Single-Center: A Retrospective Observational Study
por: Meennahalli Palleda, Girish, et al.
Publicado: (2023)

Comparisons of the Effects of Stent Eccentricity on the Neointimal Hyperplasia between Sirolimus-Eluting Stent versus Paclitaxel-Eluting Stent
por: Kim, Byeong-Keuk, et al.
Publicado: (2010)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

Antibiotic eluting sinus stents
por: Thompson, Harrison M., et al.
Publicado: (2020)

Ureteral stent technology: Drug-eluting stents and stent coatings
por: Yang, Luo, et al.
Publicado: (2015)

Stent Fracture after Everolimus-Eluting Stent Implantation
por: Almasood, Ali S., et al.
Publicado: (2011)

Early definite stent thrombosis with everolimus-eluting stents
por: Naito, Ryo, et al.
Publicado: (2015)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis
por: Pleva, Leos, et al.
Publicado: (2017)

Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions
por: Chieffo, Alaide, et al.
Publicado: (2007)

Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
por: Velders, Matthijs A., et al.
Publicado: (2013)

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?
por: Gherasie, Flavius-Alexandru, et al.
Publicado: (2023)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Everolimus-eluting stents in interventional cardiology
por: Townsend, Jacob C, et al.
Publicado: (2012)

Drug-eluting metallic stents in urology
por: Kallidonis, Panagiotis S., et al.
Publicado: (2014)

Individual patient data analysis of the BIOFLOW study program comparing safety and efficacy of a bioresorbable polymer sirolimus eluting stent to a durable polymer everolimus eluting stent
por: Toelg, Ralph, et al.
Publicado: (2020)

Comparison of neointimal coverage between ultrathin biodegradable polymer‐coated sirolimus‐eluting stents and durable polymer‐coated everolimus‐eluting stents: 6 months optical coherence tomography follow‐up from the TAXCO study
por: Abhyankar, Atul, et al.
Publicado: (2020)

Miniaturized Self-Expanding Drug-Eluting Stent in Small Coronary Arteries: Late Effectiveness
por: de Oliveira, Flavio Roberto Azevedo, et al.
Publicado: (2013)

Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions
por: Kassaian, SE, et al.
Publicado: (2010)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V(®))
por: Sheiban, Imad, et al.
Publicado: (2008)

Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
por: Velders, Matthijs A., et al.
Publicado: (2013)

Polymer-free drug-eluting stents versus permanent polymer drug-eluting stents: An updated meta-analysis
por: Chen, Yun-lin, et al.
Publicado: (2019)

Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes
por: Kakizaki, Ryota, et al.
Publicado: (2020)

Case series of coronary artery aneurysms after Everolimus eluting stent implantation and comparison with Sirolimus eluting stents
por: Sharma, Raghav, et al.
Publicado: (2022)

Safety and efficacy of biolimus-eluting stent with biodegradable polymer: insights from EINSTEIN (Evaluation of Next-generation drug-eluting STEnt IN patients with coronary artery disease) Registry
por: de Souza, Cristiano Freitas, et al.
Publicado: (2013)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Advances in drug eluting stents – focus on the Endeavor(®) zotarolimus stent
por: Bridges, Jonathan, et al.
Publicado: (2008)

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
por: Whitbeck, Matthew G., et al.
Publicado: (2013)

Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents
por: Kim, J-S, et al.
Publicado: (2009)

The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty
por: Oh, Pyung Chun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pb79ttelphuh12s8rl8dquhvl6